


RealRate

## PHARMACEUTICAL 2018

## Allergan plc Rank 46 of 349





## PHARMACEUTICAL 2018



## Allergan plc Rank 46 of 349

The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 194% points. The greatest weakness of Allergan plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 364% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	11,376,700
Cost of Goods Sold	0
Intangible Assets	104,511,200
Liabilities, Current	9,848,100
Liabilities, Non-Current	886,900
Other Assets	668,600
Other Compr. Net Income	2,952,500
Other Expenses	11,589,500
Other Liabilities	33,769,800
Other Net Income	-4,868,100
Property and Equipment	1,785,400
Research and Development	2,100,100
Revenues	15,940,700
Selling, General and Administrative Expense	1,501,900

Output Variable	Value in 1000 USD
Assets	118,341,900
Liabilities	44,504,800
Expenses	15,191,500
Stockholders Equity	73,837,100
Net Income	-4,118,900
Comprehensive Net Income	-2,642,650
Economic Capital Ratio	87%